Seven Fleet Capital Management LP Purchases New Shares in Athira Pharma, Inc. $ATHA

Seven Fleet Capital Management LP purchased a new position in Athira Pharma, Inc. (NASDAQ:ATHA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 127,951 shares of the company’s stock, valued at approximately $969,000. Athira Pharma comprises approximately 0.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 25th biggest position.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Perceptive Advisors LLC raised its stake in shares of Athira Pharma by 244.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock valued at $14,075,000 after acquiring an additional 1,319,026 shares during the period. Commodore Capital LP purchased a new position in shares of Athira Pharma during the 4th quarter worth about $3,515,000. ADAR1 Capital Management LLC purchased a new position in shares of Athira Pharma during the 4th quarter worth about $2,891,000. Spruce Street Capital LP bought a new position in Athira Pharma during the 4th quarter valued at about $2,980,000. Finally, Millennium Management LLC bought a new position in Athira Pharma during the 4th quarter valued at about $2,456,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

Athira Pharma Price Performance

Athira Pharma stock opened at $8.22 on Friday. The firm has a market capitalization of $32.42 million, a P/E ratio of -0.85 and a beta of 2.79. Athira Pharma, Inc. has a 1-year low of $0.23 and a 1-year high of $8.36. The company’s 50-day moving average is $9.33 and its 200 day moving average is $7.44.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical?stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease?modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH?1017), a small?molecule positive modulator of the HGF/MET system.